K Number
K980645
Device Name
PHILIPS GYROSCAN NT RELEASE 6 SERIES
Date Cleared
1998-05-11

(81 days)

Product Code
Regulation Number
892.1000
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
The Philips Gyroscan NT Release 6 series have the same intended use as its predecessor and predicate device Gyroscan NT Release 5. The Gyroscan NT systems are indicated for use as diagnostic devices that produce transverse, sagittal, coronal and oblique cross-sectional images, spectroscopic images and/or spectra. based upon 'H and ''P metabolites, and that display the internal structure and/or function of the head, body or extremities. These images and/or spectra when interpreted by a trained physician. yield information that may assist in diagnosis.
Device Description
The predicate device Gyroscan NT Release 5 series with the additions mentioned hereafter is called Gyroscan NT Release 6 series. - The Synergy coils are based on the same principles of the existing Philips synergy coil but their physical design is as such for better matching with the ROI to be imaged. - Synergy Body coil: This coil consists of four coil elements to image the ROI in the abdomen and the pelvic or thoracic area. - Synergy Cardiac: This coil consists of 5 coil elements to image the heart and its coronary vessels - Contrast Enhanced Angiography (CE-MRA) Package - BolusTrak. - Contrast Enhanced Peripheral Angiography Package - MobiTrak. - Respiratory Navigators (MotionTrak) is an extension to the MR Cardiography package which offers the possibility to monitor the diaphragm position of the patient during scanning. Additional MR signals are acquired interleaved with the normal MR acquisition and evaluated in real-time. These navigator signals are used to determine the position of the imaging volume to enable gating and slice correction. - MR Neuro Imaging Package provide dedicated acquisition, reconstruction techniques resulting in functional rather than anatomical information. It contains: o MR Perfusion Package. Enhanced 3D FFE and 3D FFE-EPI techniques , so-called PRESTO, which allows fast acquistion with large anatomical coverage. It provides high temporal information for evaluation of dynamic contrast agent studies. o MR Bold Imaging Package. Extensions to the PRESTO technique with respect to motion correction, acquistion and recontruction, which offers the possibility of visualization of small susceptibility changes. Introduction of Gyroscan CMR: The dedicated cardiac version , based on the Gyroscan NT platform, will be marketed as Gyroscan CMR. The latter has the same performance as the NT version except for its appearance, i.e. the name and the color of the system covers.
More Information

No
The document describes hardware and software updates focused on imaging techniques and coil design, with no mention of AI or ML.

No
The device is indicated for use as a diagnostic device to produce images and spectra that assist in diagnosis, not for therapeutic purposes.

Yes

The "Intended Use / Indications for Use" section explicitly states, "The Gyroscan NT systems are indicated for use as diagnostic devices."

No

The device description explicitly mentions physical components like "Synergy coils" and describes their "physical design," indicating it is a hardware-based medical device with software components, not a software-only device.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Device Function: The Philips Gyroscan NT Release 6 series is a Magnetic Resonance (MR) imaging system. It produces images and/or spectra of the internal structure and/or function of the head, body, or extremities. This is an in vivo diagnostic method, meaning it examines the body directly, not through a sample taken from the body.
  • Intended Use: The intended use clearly states it produces images and/or spectra based on metabolites and displays internal structure and/or function. This aligns with the function of an MR imaging system, not an IVD.

Therefore, the Philips Gyroscan NT Release 6 series is a medical imaging device used for in vivo diagnosis, not an in vitro diagnostic device.

N/A

Intended Use / Indications for Use

The Philips Gyroscan NT Release 6 series have the same intended use as its predecessor and predicate device Gyroscan NT Release 5. The Gyroscan NT systems are indicated for use as diagnostic devices that produce transverse, sagittal, coronal and oblique cross-sectional images, spectroscopic images and/or spectra. based upon 'H and ''P metabolites, and that display the internal structure and/or function of the head, body or extremities. These images and/or spectra when interpreted by a trained physician. yield information that may assist in diagnosis.

Product codes

LNH

Device Description

The predicate device Gyroscan NT Release 5 series with the additions mentioned hereafter is called Gyroscan NT Release 6 series.

  • The Synergy coils are based on the same principles of the existing Philips synergy coil but their physical design is as such for better matching with the ROI to be imaged.
  • Synergy Body coil: This coil consists of four coil elements to image the ROI in the abdomen and the pelvic or thoracic area.
  • Synergy Cardiac: This coil consists of 5 coil elements to image the heart and its coronary vessels
  • Contrast Enhanced Angiography (CE-MRA) Package - BolusTrak. The BolusTrak package allows synchronization of a (3D FFE) Contrast Enhanced (CE) MRA scan with the arterial arrival of an intravenously injected contrast agent. After the administration of the contrast agent a rapid 2D FFE thick slice dynamic scan is started with real-time reconstruction, complex substraction and viewing. At the moment the bolus is observed in the volume of interest a slower 3D FFE scan is started..
  • Contrast Enhanced Peripheral Angiography Package - MobiTrak. The MobiTrak package allows rapid evaluation of the aorta and lower extremity vasculature. It is an extension of contrast enhanced MRA, combining the advantages of 3D FFE CE acquistion with table movement between successive coronal acquisitions to overcome the limitation of a single field-of-view in relation to the large region-of-interest.
  • Respiratory Navigators (MotionTrak) is an extension to the MR Cardiography package which offers the possibility to monitor the diaphragm position of the patient during scanning. Additional MR signals are acquired interleaved with the normal MR acquisition and evaluated in real-time. These navigator signals are used to determine the position of the imaging volume to enable gating and slice correction.
  • MR Neuro Imaging Package provide dedicated acquisition, reconstruction techniques resulting in functional rather than anatomical information. It contains:
    o MR Perfusion Package. Enhanced 3D FFE and 3D FFE-EPI techniques , so-called PRESTO, which allows fast acquistion with large anatomical coverage. It provides high temporal information for evaluation of dynamic contrast agent studies.
    o MR Bold Imaging Package. Extensions to the PRESTO technique with respect to motion correction, acquistion and recontruction, which offers the possibility of visualization of small susceptibility changes.

Mentions image processing

Yes

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Magnetic Resonance

Anatomical Site

head, body or extremities, abdomen, pelvic or thoracic area, heart and its coronary vessels, aorta and lower extremity vasculature

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Trained physician

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Not Found

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K963990

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc)

Not Found

§ 892.1000 Magnetic resonance diagnostic device.

(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.

0

Image /page/0/Picture/1 description: The image shows the word "PHILIPS" in large, bold, black letters. Above the word "PHILIPS" is the number "480645" written in black ink. The text is centered on a white background. The image appears to be a logo or brand name.

Philips Medical Systems

XJR-148-3145/bf2 1998-02-16

Page 1 of 2

510(K) SUMMARY OF SAFETY AND EFFECTIVENESS.

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92.

Company Name:Philips Medical Systems North America Company.
Address:710 Bridgeport Avenue
Shelton, CT 06484.
Registration No.:1217116
Contact person:Peter Altman
Telephone Number:203-926-7031
Prepared:Februrary 16, 1998.
Device Name:Philips Gyroscan NT Release 6 series.
Classification Name:Magnetic Resonance Diagnostic Device.
Classification:Class II.
Performance standards:NEMA voluntary standards, FDA MRI guidances, UL and IEC 601
relevant safety standards and/or draft standards are used.
Common/Usual Name:Philips Gyroscan NT(*) Release 6 series.
Predicate Device(s):Philips Gyroscan NT Release 5 series (FDA re.K963990).

Intended Use :

The Philips Gyroscan NT Release 6 series have the same intended use as its predecessor and predicate device Gyroscan NT Release 5. The Gyroscan NT systems are indicated for use as diagnostic devices that produce transverse, sagittal, coronal and oblique cross-sectional images, spectroscopic images and/or spectra. based upon 'H and ''P metabolites, and that display the internal structure and/or function of the head, body or extremities. These images and/or spectra when interpreted by a trained physician. yield information that may assist in diagnosis.

Description :

The predicate device Gyroscan NT Release 5 series with the additions mentioned hereafter is called Gyroscan NT Release 6 series.

  • The Synergy coils are based on the same principles of the existing Philips synergy coil but their physical design is as such for better matching with the ROI to be imaged.
  • Synergy Body coil: This coil consists of four coil elements to image the ROI in the abdomen and the pelvic or thoracic area.
  • Synergy Cardiac: This coil consists of 5 coil elements to image the heart and its coronary vessels

(*) By Gyroscan NT is meant all three versions. I e T5-NT (0.5T), T10-NT (1.0T) and ACS-NT (1.5T).

1

Image /page/1/Picture/0 description: The image shows the text "Philips Medical Systems". The text is in a bold, sans-serif font. The text is black and is on a white background.

Image /page/1/Picture/1 description: The image shows the word "PHILIPS" in bold, black letters. The font is sans-serif and the letters are closely spaced together. The word is centered and takes up most of the frame. The background is plain white.

XJR-148-3145/bf2 1998-02-16 Page 2 of 2

- Contrast Enhanced Angiography (CE-MRA) Package - BolusTrak.

The BolusTrak package allows synchronization of a (3D FFE) Contrast Enhanced (CE) MRA scan with the arterial arrival of an intravenously injected contrast agent. After the administration of the contrast agent a rapid 2D FFE thick slice dynamic scan is started with real-time reconstruction, complex substraction and viewing. At the moment the bolus is observed in the volume of interest a slower 3D FFE scan is started..

- Contrast Enhanced Peripheral Angiography Package - MobiTrak.

The MobiTrak package allows rapid evaluation of the aorta and lower extremity vasculature. It is an extension of contrast enhanced MRA, combining the advantages of 3D FFE CE acquistion with table movement between successive coronal acquisitions to overcome the limitation of a single field-of-view in relation to the large region-of-interest.

  • Respiratory Navigators (MotionTrak) is an extension to the MR Cardiography package which offers the possibility to monitor the diaphragm position of the patient during scanning. Additional MR signals are acquired interleaved with the normal MR acquisition and evaluated in real-time. These navigator signals are used to determine the position of the imaging volume to enable gating and slice correction.

  • MR Neuro Imaging Package provide dedicated acquisition, reconstruction techniques resulting in functional rather than anatomical information. It contains:

o MR Perfusion Package. Enhanced 3D FFE and 3D FFE-EPI techniques , so-called PRESTO, which allows fast acquistion with large anatomical coverage. It provides high temporal information for evaluation of dynamic contrast agent studies.

o MR Bold Imaging Package. Extensions to the PRESTO technique with respect to motion correction, acquistion and recontruction, which offers the possibility of visualization of small susceptibility changes.

Introduction of Gyroscan CMR:

The dedicated cardiac version , based on the Gyroscan NT platform, will be marketed as Gyroscan CMR. The latter has the same performance as the NT version except for its appearance, i.e. the name and the color of the system covers.

Technological Characteristics:

The technological characteristics remain the same as those for other Gyroscan NT systems. New coils and sequences are available as the options are enabled.

General Safety and Effectiveness Concerns

The Philips GYROSCAN NT Release 6 series contains extensions to the Release 5 series which do not induce any other risks than the already known with MRI techniques.

Substantial Equivalence

The Philips GYROSCAN NT Release 6 series devices are substantially equivalent to the predicate devices of GYROSCAN NT Release 5 series.

2

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Image /page/2/Picture/3 description: The image shows a partial view of a logo or emblem, featuring stylized, thick, black lines that appear to be abstract representations of waves or flowing elements. The lines are curved and stacked on top of each other, creating a sense of movement and depth. To the left of the abstract lines, there are partial letters, oriented vertically, which seem to be part of a word or phrase, possibly indicating the name of an organization or department.

। । MAY

Peter Altman Director of Regulatory Affairs Philips Medical Systems North America Company 710 Bridgeport Avenue P.O. Box 860 Shelton, CT 06484-0917

Re:

K980645

Philips GYROSCAN NT Release 6 Series February 18, 1998 Dated: Received: February 19, 1998 Regulatory class: II 21 CFR 892.1000/Procode: 90 LNH

Dear Mr. Altman:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsmadsmamain.html".

Sincerely yours,

William Yin

Lillian Yin, Ph.D. Director, Division of Reproductive Abdominal, Ear, Nose and Throa and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

3

Unknown 180645 510(k) Number (if known): Philips GYROSCAN NT Release 6 series Device Name :

Indication For Use :

The Philips Gyroscan NT Release 6 series have the same intended use as its predecessor and predicate device Gyroscan NT Release 5. The GYROSCAN NT systems are indicated for use as diagnostic devices that produce transverse, sagittal, coronal and oblique cross-sectional images, spectroscopic images and/or spectra, based upon 'H and 3'P metabolites, and that display the internal structure and/or function of the head, body or extremities. These images and/or spectra when interpreted by a trained physician, yield information that may assist in diagnosis.

( PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH. Office of Device Evaluation (ODE)

David A. Seymann
(Division Sign-Off)

Division of Reproductive, Abdominal, El and Radiological Devic

510(k) Number K980645

Prescription Use (Per 21 CFR 801.109) OR

ﺃﻧﻈﻤﺔ ﺍﻟﻤﺴﺎﺣﺔ

Over-The-Counter Use

(Optional Format 1-2-96)